Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Artemisinin Resistance In Malaria Treated With IV Artesunate (ARIMTIA)

20. august 2018 opdateret af: University of Oxford

A Multicenter, Prospective, Observational Study to Assess the Efficacy of Artesunate in Malaria Treated With Parenteral Artesunate in Areas With Artemisinin Resistance A Study by the Tracking Resistance to Artemisinin Collaboration (TRAC)

The spread of artemisinin resistant falciparum malaria presents new challenges to both the control and treatment of malaria. Loss of ring stage susceptibility to the artemisinins might jeopardize the use of parenteral artesunate as the first line drug for the treatment of severe falciparum malaria.

The purpose of this study is to assess the effect of artemisinin resistance (defined by a Kelch13 mutation with known functional significance) in P. falciparum malaria requiring parenteral artesunate treatment on lactate clearance parameters.

Studieoversigt

Status

Trukket tilbage

Betingelser

Intervention / Behandling

Detaljeret beskrivelse

The investigators propose a multi-center observational study to assess the effect of artemisinin resistance (as defined by the presence of relevant Kelch13 mutations) on the efficacy of parenteral artesunate for the treatment of malaria, stratified for disease severity on admission.

The patients will receive the standard intravenous treatment for severe malaria (parenteral artesunate). Primary endpoints will be the plasma lactate concentration at 12 hours as a proportion of the plasma lactate at the start of treatment. Secondary endpoints will be improvement of Glasgow or Blantyre Coma Scores and other indicators of neurological recovery or deterioration, parasite clearance rates, time until resolution of fever, development of new severity or neurological signs under treatment, development of severe anemia, renal and hepatic injury, total duration of hospitalization , outcome of pregnancy in pregnant female patients, mortality rates and the necessity to treat with antibiotics, need for renal replacement therapy, mechanical ventilation, blood transfusion and rescue treatments.

On admission blood will be taken for the determination of genetic markers of antimalarial resistance (including Kelch13 mutations of known functional significance) and in vitro sensitivity tests to artemisinins and other antimalarials. Additional blood samples will be used for measuring plasma organic acid biomarkers of severe falciparum malaria measured by mass spectrometry. Difference in the kinetics of these acids will be an additional endpoint. Difference in the transcriptome of p. falciparum will be assessed by RNA measurements at baseline and 3 timepoints during treatment.

The proposed sites in Vietnam and Cambodia have been chosen based on the prevalence of artemisinin resistant falciparum malaria, incidence of severe malaria and local experience in participating in clinical trials.

Interim analysis:

To ensure timely recognition of the effect of artemisinin resistance on the outcome in malaria treated with parenteral artesunate, an interim analysis will be performed after the inclusion of 60 patients or one malaria transmission season (whatever comes first). An independent Data Safety Board will assess whether the difference in outcome between infections with artemisinin resistant versus sensitive strains warrants early termination and reporting of the study.

Undersøgelsestype

Observationel

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

6 måneder og ældre (Barn, Voksen, Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Prøveudtagningsmetode

Ikke-sandsynlighedsprøve

Studiebefolkning

Patients admitted with malaria, caused by Plasmodium falciparum, treated with parenteral artesunate.

Beskrivelse

Inclusion Criteria:

  • Male or female, aged over 6 months old

  • Acute severe P. falciparum malaria or another indication to treat with IV artesunate. Defined as one or more of the following, occurring in the absence of an identified alternative cause, and in the presence of P. falciparum asexual parasitaemia:

    • Prostration OR obtundation
    • BCS<3 (preverbal children) or GCS<11 (adults)
    • Convulsion in last 24 hours
    • Suspected acidosis, manifesting as acidotic breathing
    • Respiratory distress manifesting clinically (nasal flaring/indrawing) or oxygen saturation <92% or respiratory rate >30/min
    • History of anuria
    • Jaundice and/or hemoglobinuria
    • Hemoglobin <7 g/dl or hematocrit <20%
    • Significant bleeding including recurrent or prolonged bleeding from nose gums or venipuncture sites; hematemesis or melena
    • Shock defined as systolic blood pressure <70 mm Hg (children) OR <80 mm Hg (adults)
    • P. falciparum parasitaemia >10%

    • Indication for parenteral antimalarial treatment (as assessed by clinician) other than nausea and vomiting. These may include laboratory findings such as:

      • Creatinine >2.5 mg/dL (>220uM/L) or blood urea >56mg/dL (>20 mM/L)
      • Glucose <4.0 mmol/L (<72mg/dL)
      • Bilirubin > 3 mg/dL (>50uM/L)
      • Hemoglobin <7g/dL or Hematocrit <20%
      • P. falciparum parasitaemia >4%
      • Venous plasma lactate >5 mM, Base deficit of >8meq/L or bicarbonate <15mM
    • Written informed consent or consent by locally accepted representative in the case of patients rendered incapable of providing consent due to illness

Exclusion Criteria:

  • History of 2 or more doses of parenteral antimalarial treatment in the previous 24 hours
  • History of allergy or known contraindication to artemisinins

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

Kohorter og interventioner

Gruppe / kohorte
Intervention / Behandling
Study subjects
Patients admitted with malaria, caused by Plasmodium falciparum, treated with parenteral artesunate.
Medicin: Intravenous Artesunate as part of standard medical practice
Intravenous Artesunate 2.4 mg/kg

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Absolute reduction of lactate
Tidsramme: 12 hours
Absolute reduction of lactate at 12 hours after the first artesunate treat-ment compared to baseline.
12 hours

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Time needed until a plasma lactate concentration <2 mmol/L
Tidsramme: 42 days
42 days
Change in Glasgow Coma Score (GCS) or Blantyre Coma Score (BCS)
Tidsramme: 12 hours
at 12 hours after initial treatment and coma recovery time defined as GCS>10 or BCS>3 and GCS=15 and BCS=5
12 hours
Base excess clearance after 12 hours
Tidsramme: 42 days
Base excess clearance after 12 hours as proportion of the base excess at presentation
42 days
Time until a base excess concentration ≥ minus 2 mmol/L
Tidsramme: 42 days
42 days
Time to resuming the ability to sit, eat, drink, stand unsupported and walk
Tidsramme: 42 days
42 days
The parasite clearance half-life
Tidsramme: 48 hours
48 hours
The parasite clearance ratios at H28 and H48 compared to parasite count on admission
Tidsramme: 48 hours
48 hours
The parasite clearance time for parasite count to fall to 50%, 90% and 99% of initial parasite density
Tidsramme: 7 days
7 days
Differences in transcriptome patterns between artemisinin resistant parasites and artemisinin sensitive parasites at baseline
Tidsramme: H0
H0
Differences in transcriptome patterns between artemisinin resistant parasites and artemisinin sensitive parasites at H6
Tidsramme: H6
H6
Differences in transcriptome patterns between artemisinin resistant parasites and artemisinin sensitive parasites at H12
Tidsramme: H12
H12
Differences in transcriptome patterns between artemisinin resistant parasites and artemisinin sensitive parasites at H48
Tidsramme: H48
H48
Time until resolution of fever
Tidsramme: 14 days
(time until tympanic temperature first <37.5 Celsius and below 37.5C for 24 h)
14 days
Proportion of patients developing new malaria
Tidsramme: 42 days
Proportion of patients developing new malaria severity signs as defined in the 2014 WHO severe malaria guidelines
42 days
Proportion of patients developing new neurological signs assessed by neurological examination during hospitalization
Tidsramme: 42 days
42 days
Prevalence of neurological sequelae assessed by neurological examination at discharge
Tidsramme: 42 days
42 days
Prevalence of neurological sequelae assessed by neurological examination at day 7
Tidsramme: 7 days
7 days
Prevalence of neurological sequelae assessed by neurologicalexamination at day 14
Tidsramme: 14 days
14 days
Prevalence of neurological sequelae assessed by neurological examination at day 28 if day 14 is abnormal
Tidsramme: 28 days
28 days
Prevalence of neurological sequelae assessed by neurological examination at day 42 if day 28 is abnormal
Tidsramme: 42 days
42 days
Severity of neurological sequelae assessed by neurological examination at discharge
Tidsramme: 42 days
42 days
Severity of neurological sequelae assessed by neurological examination at day 7
Tidsramme: 7 days
7 days
Severity of neurological sequelae assessed by neurological examination at day 14
Tidsramme: 14 days
14 days
Severity of neurological sequelae assessed by neurological examination at day 28 if day 14 is abnormal
Tidsramme: 28 days
28 days
Severity of neurological sequelae assessed by neurological examination at day 42 if day 28 is abnormal
Tidsramme: 42 days
42 days
Proportion treated with quinine
Tidsramme: 42 days
as a rescue treatment, antibiotics, blood products, anticonvulsants, renal replacement therapy, mechanical ventilation therapy, vasopressive drugs and oxygen therapy
42 days
In hospital mortality
Tidsramme: 42 days
42 days
Day 7, 14 hemoglobin or hematocrit levels
Tidsramme: 42 days
and in addition at day 28 and 42 if abnormal at day 14 or day 28 respectively
42 days
Creatinine levels daily
Tidsramme: 42 days
during the first four days and thereafter on day 7 and 14 and in addition on day 28 and 42 if abnormal on day 14 or day 28 respectively
42 days
Bilirubin, Alanine transaminase (ALT), aspartate aminotransferase (AST) and alkaline phosphatase levels daily
Tidsramme: 42 days
during the first four days and thereafter on day 7, 14 and in addition on day 28 and 42 if abnormal on day 14 or 28 respectively
42 days
Plasma biomarkers of severe (artemisinin resistant) malaria
Tidsramme: 42 days
42 days
outcome of pregnancy during hospitalization
Tidsramme: 42 days
If pregnant
42 days
Time until discharge
Tidsramme: 42 days
42 days

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Sponsor

University of Oxford

Samarbejdspartnere

Oxford University Clinical Research Unit, Vietnam
Mahidol Oxford Tropical Medicine Research Unit

Efterforskere

  • Ledende efterforsker: Prof. Arjen M Dondorp, MD, Mahidol Oxford Research Unit (MORU)

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

1. oktober 2015

Primær færdiggørelse (Faktiske)

1. december 2017

Studieafslutning (Faktiske)

1. december 2017

Datoer for studieregistrering

Først indsendt

16. november 2015

Først indsendt, der opfyldte QC-kriterier

22. december 2015

Først opslået (Skøn)

29. december 2015

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

22. august 2018

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

20. august 2018

Sidst verificeret

1. august 2018

Mere information

Begreber relateret til denne undersøgelse

Nøgleord

Yderligere relevante MeSH-vilkår

Andre undersøgelses-id-numre

  • BAKMAL1504

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Kliniske forsøg med Malaria

Søg i lignende forsøg

Sponsorer og samarbejdspartnere

Medicinske tilstande

Narkotikainterventioner

CROs by country

CROs in Myanmar

Betingelser

Sjældne sygdomme

Narkotikainterventioner

Kosttilskud

Sponsor / samarbejdspartnere

Placeringer

Abonner